Revelation Biosciences Extends Stock Warrants Expiration
I'm PortAI, I can summarize articles.
Revelation Biosciences announced the extension of Class I Common Stock Warrants expiration to December 3, 2030, following stockholder approval. The company completed a Phase 1b clinical study for Gemini in CKD patients, showing promising inflammation treatment results. They plan to advance Gemini's development for acute kidney injury treatment, aiming for Phase 2 or 3 trials in 2026. Analysts rate REVB stock as a Buy with a $20 target, despite financial challenges and bearish technical indicators.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments